Prostate cancer, explained from the guidelines

Prostate cancer is the most common cancer in men in the United States. The NCCN guideline cites an estimated 288,300 new cases and 34,700 deaths in 2023, and a lifetime risk of about 1 in 8. Behind those numbers is a very wide range of disease. Some prostate cancers grow so slowly that they are unlikely ever to cause harm, while others can spread and threaten life.

Because of that range, modern care starts by working out how aggressive a particular cancer is likely to be. Guidelines sort newly diagnosed cancers into risk groups, and the recommended approach depends on the risk group, a man's overall health and life expectancy, and what matters most to him. For the lowest-risk cancers, guidelines recommend careful monitoring, called active surveillance, rather than immediate treatment.

This page draws on four AUA guidelines (localized disease, early detection, advanced disease and salvage therapy), the NCCN Clinical Practice Guidelines in Oncology, and the European Association of Urology (EAU) guideline. It is educational only and cannot replace a conversation with your own care team, who know the details of your situation.

The prostate is a small gland that sits just below the bladder and in front of the rectum. The urethra, the tube that carries urine out of the body, runs through its middle. The prostate makes part of the fluid in semen, and its cells depend on male hormones (androgens) such as testosterone to grow.

Almost all prostate cancers are adenocarcinomas, meaning they start in the gland cells that make prostate fluid. A pathologist grades how abnormal the cancer cells look under the microscope using the Gleason system, which is now reported as a Grade Group from 1 (least aggressive) to 5 (most aggressive).

As it grows, prostate cancer can push through the thin capsule around the gland, into the seminal vesicles (two small glands behind the prostate), into lymph nodes in the pelvis, and later to bones or other organs. Because prostate cancer cells usually need androgens, lowering testosterone (hormone therapy) is a central treatment once the disease has spread. Over time, some cancers learn to grow despite very low testosterone; this is called castration-resistant prostate cancer.

Age is the strongest risk factor; the EAU guideline notes that how often prostate cancer occurs depends mainly on age. Ancestry and family history also matter. The AUA/ASTRO/SUO salvage guideline notes that Black men in the United States have the highest incidence of prostate cancer and more than double the death rate of other racial and ethnic groups. The AUA early detection guideline names Black ancestry, inherited gene mutations and a strong family history as reasons to start screening earlier.

Inherited changes in DNA repair genes, especially BRCA2, raise the chance of prostate cancer and of more aggressive disease. The EAU guideline reports that in a large US study, 15.6% of men with prostate cancer carried a harmful inherited variant, most often in BRCA2 (4.5%). Other genes linked to higher risk include ATM, CHEK2, BRCA1, HOXB13 and the mismatch repair genes that cause Lynch syndrome. A positive result can affect treatment choices and can matter for relatives.

Many dietary and lifestyle factors have been studied. The EAU guideline concludes that the evidence does not show that any specific food or supplement causes or prevents prostate cancer, and that no proven preventive diet or medicine exists. Current smoking has been linked to a higher risk of dying from prostate cancer. Vasectomy, once suspected, has been shown not to raise risk.

Early prostate cancer rarely causes symptoms of its own. The EAU guideline notes that it is usually suspected because of a raised PSA blood test or an abnormal digital rectal exam (DRE), in which a doctor feels the back of the prostate with a gloved finger. Urinary symptoms such as a weak stream or getting up at night are common as men age and often have other causes, such as benign enlargement of the prostate.

PSA (prostate-specific antigen) is a protein made by the prostate. It is specific to the prostate but not to cancer, so it can also rise with benign enlargement, infection or inflammation, and medicines such as finasteride or dutasteride can lower it by about half. The AUA recommends repeating a newly raised PSA before moving on to further tests, and the EAU gives similar advice.

Screening is a personal decision made with your clinician. The AUA says clinicians may offer a baseline PSA between ages 45 and 50, should offer screening from age 40 to 45 to men at higher risk, and should offer regular screening every 2 to 4 years to men aged 50 to 69. The EAU recommends counselling before any PSA test and early testing from age 50, from age 45 for men of African descent or with a family history, and from age 40 for BRCA2 carriers.

Advanced prostate cancer can cause symptoms such as bone pain, blood in the urine, worsening urinary or bowel problems, swelling of the legs, fatigue or unexplained weight loss. The EAU lists these as reasons to check a PSA in men who are not being tested regularly.

If PSA stays raised, the next steps aim to find cancers that matter while avoiding unnecessary biopsies. The AUA defines clinically significant cancer as Grade Group 2 or higher, because the risk of dying from Grade Group 1 cancer is extremely low. Validated risk calculators, prostate MRI and additional blood or urine markers can help decide whether a biopsy is worthwhile, and when risk is low enough the AUA says a near-term biopsy may reasonably be skipped.

Prostate MRI, scored with a standard system called PI-RADS, can show suspicious areas. Here the guidelines differ in emphasis: the AUA says MRI may be used before a first biopsy (a conditional recommendation), while the EAU recommends MRI before every biopsy (strong). Both recommend MRI before a repeat biopsy. When MRI shows a suspicious area, the AUA recommends targeted biopsy of that area with at least two cores, with or without a standard systematic biopsy; if MRI is normal but risk remains elevated, a systematic biopsy is recommended.

A biopsy uses a thin needle, guided by ultrasound and often fused with the MRI images, to remove small cores of tissue. It can be done through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). The AUA accepts either route. The EAU recommends the transperineal route because studies show fewer infections, and it rates this recommendation strong even though the underlying data are of low certainty.

Before biopsy, the AUA advises telling patients that it may find a low-risk cancer that can safely be watched rather than treated. A negative biopsy is not a reason to simply stop screening; risk is reassessed using tools that take the negative result into account.

Three pieces of information describe a newly diagnosed prostate cancer: the stage (how far it has spread), the grade (how aggressive the cells look) and the PSA level. Stage uses the TNM system. T1 means the tumor cannot be felt and was found another way, most often by biopsy after a raised PSA (T1c). T2 can be felt but is confined to the prostate (T2a, half of one side or less; T2b, more than half of one side; T2c, both sides). T3 has grown through the capsule (T3a) or into the seminal vesicles (T3b). T4 is fixed to or invades nearby structures such as the rectum or pelvic wall. N1 means cancer in pelvic lymph nodes, and M1 means spread to distant lymph nodes (M1a), bones (M1b) or other organs (M1c).

Grade Group 1 corresponds to a Gleason score of 6 or less, Grade Group 2 to Gleason 3+4, Grade Group 3 to Gleason 4+3, Grade Group 4 to Gleason 8, and Grade Group 5 to Gleason 9 or 10.

The AUA recommends combining clinical T stage, PSA, Grade Group and the amount of cancer on biopsy to place each patient in a risk group. The NCCN uses six groups, shown in the table. The AUA uses the same idea but merges very low and low risk, because management is the same, and does not separate very high from high risk. The EAU uses a simpler three-tier system (low, intermediate, high) but refers to the NCCN favorable and unfavorable intermediate groups in its radiation recommendations.

Imaging for spread depends on risk. The AUA advises against routine CT or bone scans for men with low- or intermediate-risk cancer and no symptoms, and recommends a bone scan plus pelvic MRI or CT for high-risk cancer; the NCCN recommends bone and soft tissue imaging from unfavorable intermediate risk upward. PSMA PET scans are more sensitive than standard scans. The NCCN considers PSMA PET at least as effective a first imaging test and does not require standard scans first. The AUA says it may be used when standard imaging is negative in high-risk men, and the EAU recommends not changing treatment based on PSMA PET findings alone, given current data.

The AUA states that every prostate cancer treatment carries risk, especially to urinary, sexual and bowel function, and that those risks must be weighed together with the threat posed by the cancer, life expectancy, other health problems and personal preferences. This is shared decision-making: your care team brings the evidence, you bring your values, and the plan is made together. The AUA also recommends giving each patient an individualized estimate of the chance the cancer will come back after treatment.

Life expectancy matters because prostate cancer often grows slowly. For men without symptoms whose life expectancy is limited by age or other illness, the AUA recommends watchful waiting, and the EAU recommends it when life expectancy is under 10 years. Watchful waiting means no routine cancer testing, with treatment only if symptoms develop. It is different from active surveillance, which uses regular testing with the intention of curative treatment if the cancer changes.

Tissue-based genomic tests can sometimes refine risk. The AUA says they may be used selectively when the result could change a decision, but should not be used routinely. Germline genetic testing is considered based on personal and family risk factors.

Care often involves more than one specialist. Urologists perform biopsies and surgery, radiation oncologists plan radiation, and medical oncologists manage drug treatment for advanced disease. The AUA advanced prostate cancer guideline calls for a multidisciplinary approach when available, and the EAU recommends that metastatic castration-resistant disease be managed by a multidisciplinary team. For localized disease, many men meet both a urologist and a radiation oncologist before deciding.

For low-risk prostate cancer, the AUA recommends active surveillance as the preferred option. The NCCN lists active surveillance as the only recommended approach for very-low-risk disease when life expectancy is 10 years or more, and as preferred for most men with low-risk disease. The EAU likewise recommends active surveillance for low-risk disease when life expectancy is over 10 years. On this point the three guidelines agree closely.

Much of the evidence comes from the ProtecT trial, which randomly assigned 1,643 men with localized prostate cancer to surgery, radiation or active monitoring. Deaths from any cause were nearly identical across the three groups (10.1, 10.3 and 10.9 per 1,000 person-years), with no significant difference in prostate cancer deaths. Cohort studies of active surveillance for low-risk disease have consistently found low rates of spread (under 1.5%) and of prostate cancer death (under 1%) within 10 years.

Active surveillance is not the same as doing nothing. It means scheduled PSA tests, exams, MRI and repeat biopsies, with a plan to offer curative treatment if the cancer shows signs of becoming more aggressive. The AUA says MRI should be used to add information but should not replace periodic biopsy. The NCCN strongly recommends confirmatory testing within 6 to 12 months of diagnosis and a confirmatory biopsy within 1 to 2 years. The most common reason to move to treatment is finding a higher grade on repeat biopsy.

Some men with low-risk disease choose treatment after an informed discussion, and the AUA acknowledges this. If radiation is chosen for low-risk or favorable intermediate-risk disease, the AUA considers hypofractionated external beam radiation, permanent low-dose-rate seed implants and temporary high-dose-rate implants to be equivalent options, without routine hormone therapy.

Intermediate-risk prostate cancer is a broad group, which is why it is split into favorable and unfavorable subgroups. For favorable intermediate risk, the AUA recommends discussing active surveillance, radiation and radical prostatectomy. The NCCN lists the same three options and notes surveillance may suit men with little Gleason pattern 4, low tumor volume, low PSA density or a low genomic risk score. The EAU is more cautious: it offers surveillance only to highly selected men with Grade Group 2 disease (under 10% pattern 4, PSA under 10, limited extent on imaging and biopsy) as a weak recommendation, and excludes Grade Group 3.

For unfavorable intermediate risk with life expectancy over 10 years, the AUA recommends a choice between radical prostatectomy and radiation plus hormone therapy (androgen deprivation therapy, ADT). When radiation is chosen, the AUA recommends adding a short course of ADT for 4 to 6 months; for favorable intermediate risk, ADT is not routinely added. The EAU recommends short-term ADT with external beam radiation for intermediate-risk disease, and lists seed implants alone as an option for favorable intermediate risk with good urinary function.

Radical prostatectomy removes the prostate and seminal vesicles and is most often performed robotically today. The AUA recommends nerve-sparing surgery when it is safe from a cancer standpoint, to help preserve erections. Removing pelvic lymph nodes gives staging information but has not consistently improved survival, so the AUA recommends using nomograms (risk calculators) to decide who needs it, and an extended dissection when it is done. The EAU notes that no surgical approach (open, laparoscopic or robotic) has clearly shown better functional or cancer results.

Ablation of the whole gland or only the tumor area (focal therapy), for example with high-intensity focused ultrasound (HIFU) or cryotherapy, is offered at some centers. The AUA says men considering it should be told there is a lack of high-quality data comparing it with surgery, radiation and surveillance. The NCCN does not recommend these as routine first treatment because long-term comparative data are lacking, and the EAU recommends offering them only within clinical trials or registries.

High-risk cancers (PSA above 20, Grade Group 4 or 5, or stage T3) are more likely to spread and usually need active treatment. For unfavorable intermediate- or high-risk disease with life expectancy over 10 years, the AUA recommends a choice of radical prostatectomy or radiation plus ADT. Imaging to look for spread is recommended before treatment.

With radiation for high-risk disease, the AUA recommends adding long-course ADT for 18 to 36 months and says radiation to the pelvic lymph nodes may be offered. Radiation can be external beam alone or combined with a brachytherapy boost. For very-high-risk disease, the NCCN includes radiation plus ADT plus abiraterone as an option. The EAU recommends radiation with long-term ADT plus 2 years of abiraterone for men without nodal spread who have at least two of stage T3 to T4, Gleason 8 or higher, or PSA above 40, and for men whose cancer involves pelvic lymph nodes.

Surgery for high-risk disease is often the first step of a multimodal plan, meaning radiation or hormone therapy may be added later depending on the pathology and PSA. The AUA recommends completing the prostatectomy even if suspicious lymph nodes are found during the operation. After surgery, the AUA does not recommend routine adjuvant radiation (radiation given while PSA is still undetectable) and favors PSA monitoring with early salvage radiation if PSA rises; the NCCN also lists monitoring as the preferred option (category 1). The EAU differs: it recommends offering adjuvant radiation to men with Grade Group 4 or 5 and stage pT3 cancer whose nodes are negative.

The AUA and EAU both advise against focal or whole-gland ablation for high-risk cancer outside a clinical trial. For men with high-risk cancer, local symptoms and limited life expectancy, the AUA says ADT alone may be used to control symptoms.

After a prostatectomy, PSA should become undetectable. A rising PSA without visible cancer on scans is called biochemical recurrence. The AUA defines it after surgery as a PSA of 0.2 ng/mL or higher, confirmed by a second value above 0.2. After radiation, PSA falls slowly, and recurrence is usually defined by the Phoenix definition: a rise of 2 ng/mL or more above the lowest PSA reached (the nadir). A rising PSA does not always mean the cancer will cause harm. Risk depends on how quickly PSA is doubling, the original Grade Group, stage, surgical margins, genomic results and scan findings.

For a rising PSA after prostatectomy, salvage radiation to the area where the prostate was offers another chance of cure. The AUA/ASTRO/SUO guideline says it works better at lower PSA levels, recommends giving it when PSA is 0.5 ng/mL or lower, and says it may be offered below 0.2 for men at high risk of progression. The EAU recommends early salvage radiation after two consecutive PSA rises without waiting for a set threshold, suggests adding hormone therapy (a weak recommendation), and allows monitoring for men in its low-risk recurrence group.

PSMA PET scans can find recurrent cancer at lower PSA levels than CT or bone scans. The salvage guideline recommends this type of PET imaging when salvage radiation is being considered, and says lymph nodes seen on PET should be included in the radiation plan. Both the AUA and EAU agree that a negative PET scan should not by itself stop salvage radiation.

After radiation, a recurrence confined to the prostate can sometimes be treated with salvage prostatectomy, cryotherapy, HIFU or reirradiation; the NCCN lists these options, and the EAU limits them to highly selected men in experienced centers within trials or prospective studies. When PSA rises after all local options are used and scans show no spread, the AUA recommends observation or a clinical trial and says ADT should not be started routinely.

When prostate cancer has spread but still responds to lowering testosterone, it is called metastatic hormone-sensitive (or castration-sensitive) prostate cancer. The AUA recommends confirming the diagnosis with a biopsy when feasible, mapping the extent of spread, and classifying it as low or high volume. High volume means four or more bone metastases with at least one outside the spine and pelvis, or spread to organs such as the liver or lungs.

ADT is the foundation, given as injections or implants (LHRH agonists or antagonists) or by surgical removal of the testicles (orchiectomy). The guidelines agree that ADT alone is no longer enough for most men who can tolerate more. The AUA recommends combining ADT with an androgen pathway drug (abiraterone with prednisone, apalutamide or enzalutamide) or with docetaxel chemotherapy. For selected men with spread at first diagnosis, it recommends ADT plus docetaxel plus either abiraterone or darolutamide. The EAU agrees and adds that docetaxel should be used only together with ADT and abiraterone or darolutamide.

For low-volume metastatic disease, radiation to the prostate plus ADT may be offered; the AUA rates this conditional and the EAU strong, for men whose first presentation is low-volume spread. The AUA advises against combining older antiandrogens with LHRH agonists except briefly to block the testosterone flare when injections start, and recommends offering germline genetic testing to all men with metastatic hormone-sensitive disease.

Treatment at this stage aims to control the cancer and extend life while protecting quality of life; it is not usually curative. PSA is checked every 3 to 6 months after ADT begins.

Castration-resistant prostate cancer (CRPC) means the cancer keeps growing, usually seen as a rising PSA or changes on scans, even though testosterone is at castrate levels. The EAU says testosterone must be confirmed below 50 ng/dL before making this diagnosis. ADT is usually continued.

If CRPC has not spread on scans (non-metastatic CRPC) and PSA is doubling in 10 months or less, the AUA recommends adding apalutamide, darolutamide or enzalutamide. With slower PSA doubling, observation while continuing ADT is reasonable. Chemotherapy or immunotherapy is not recommended for this group outside a clinical trial.

For metastatic CRPC there are several life-prolonging options, and the order depends on earlier treatment, symptoms, where the cancer has spread and genetic results. The AUA recommends abiraterone, enzalutamide or docetaxel for men not yet treated with androgen pathway drugs; cabazitaxel rather than a second androgen pathway drug after docetaxel and abiraterone or enzalutamide; radium-223 for painful bone metastases without organ spread; and lutetium-177 PSMA-617 for men whose cancer has progressed after docetaxel and an androgen pathway drug and who have a positive PSMA PET scan. Sipuleucel-T may be offered to men with few or no symptoms.

Genetic testing guides newer treatments. The AUA recommends germline and tumor testing for DNA repair defects, microsatellite instability and other changes. Men with harmful repair gene mutations such as BRCA2 may be offered a PARP inhibitor, and men with mismatch repair deficient or MSI-high tumors may be offered pembrolizumab. Bone-protecting drugs (denosumab or zoledronic acid) are recommended for men with CRPC and bone metastases.

All active treatments for prostate cancer can affect urinary, sexual and bowel function. In the ProtecT trial, overall quality of life did not differ between active monitoring, surgery and radiation over 5 years, but the pattern of side effects did: surgery affected urinary control and sexual function more, and radiation with 6 months of ADT affected bowel function more. Active surveillance avoids treatment side effects but involves repeat biopsies, which carry a risk of infection.

After radical prostatectomy, the most common problem is erectile dysfunction and the second is long-term urine leakage. Orgasm becomes dry because the prostate and seminal vesicles are removed. Reported rates vary widely because studies measure them differently; in one large prospective study, about 21% of men reported incontinence and about 70% erectile dysfunction 12 months after robotic surgery, similar to open surgery. Leakage is treated first with pelvic floor muscle training, and if it persists, with a male sling or artificial urinary sphincter. Erection medicines (PDE5 inhibitors) can help, though the EAU finds the evidence on early penile rehabilitation mixed.

External beam radiation can cause bowel urgency, diarrhea, rectal bleeding and urinary irritation; modern intensity-modulated radiation (IMRT) causes less bowel toxicity than older methods. Erection problems develop gradually after radiation, at a median of about 25% at 2 years with IMRT. Seed implants more often cause irritative urinary symptoms in the first year and sometimes urinary retention. Radiation brings a small long-term increase in bladder and rectal cancers (an absolute excess risk of 1% to 4% over 10 years), which matters most for younger men.

Hormone therapy lowers testosterone, so it commonly causes loss of sex drive and erections, hot flashes (in 44% to 80% of men), fatigue, loss of muscle and gain in fat, bone thinning with higher fracture risk, raised blood sugar and cholesterol, and mood changes. The AUA recommends assessing fracture risk and advising calcium, vitamin D, weight-bearing exercise and stopping smoking, with bone-strengthening medicines for men at high risk. Supervised exercise during ADT improves fitness, muscle mass and fatigue.

PSA testing is the cornerstone of follow-up. After a successful prostatectomy, PSA should be undetectable within about 2 months. After radiation, PSA falls slowly and can take 3 years or more to reach its lowest point. Follow-up is closer in the first few years, when the chance of recurrence is highest; the EAU notes that most recurrences after local treatment occur within 7 years, though some appear much later.

Schedules differ slightly between guidelines, and the EAU notes that the evidence for any specific interval is low. Scans are not part of routine follow-up while PSA is stable. They are used when PSA rises or new symptoms appear, and only when the result would change treatment. Your care team may test more often if your risk is higher.

Sexual health deserves the same attention as PSA results. Changes in erections, ejaculation, orgasm and desire are common, some men notice a change in penile length after surgery, and men on hormone therapy often lose interest in sex altogether. Treatments for erectile dysfunction exist, and it helps to raise these concerns early rather than wait. Men who may want children in the future should mention this before treatment, because surgery ends ejaculation and other treatments can affect fertility.

Urine leakage is common early after surgery and often improves over the following months. Pelvic floor muscle training is the usual first step, and for leakage that persists, a male sling or artificial urinary sphincter can reduce pad use and improve quality of life. Bowel or bladder irritation after radiation is also worth reporting, because it can often be treated.

A prostate cancer diagnosis affects mood, relationships and sense of self. Hormone therapy can add depression, anxiety, irritability and changes in body shape. The AUA recommends continued symptom management and encouraging men to use professional and community resources, including peer support and patient advocacy groups. The EAU describes nurse-led rehabilitation programs that improved sexual function and reduced cancer worry, and exercise programs that improved fitness and fatigue.

The NCCN states that the best management of any patient with cancer is in a clinical trial, and it encourages participation. Several guideline statements point specifically to trials: the EAU limits focal therapy and metastasis-directed treatment to trials or registries, and the AUA recommends observation or a trial for men with a rising PSA after all local treatment and no visible spread. It is always reasonable to ask whether a trial fits your situation.

Because localized prostate cancer often has more than one reasonable option, many men meet both a urologist and a radiation oncologist, and some seek a second opinion before deciding. The guidelines emphasize that the final choice should reflect your values, so it is worth taking the time you need when the cancer is low or intermediate risk.

The AUA/ASTRO/SUO salvage guideline notes that health inequities have been documented at every stage of prostate cancer care, including access to newer imaging and enrollment in trials. Asking directly about trials, genetic testing and newer scans helps make sure these options are considered.

Most follow-up happens on a routine schedule, but some symptoms need prompt attention. After a biopsy or surgery, fever, chills or being unable to pass urine should be reported the same day. During treatment, report new or worsening urinary, bowel or sexual problems at your next contact rather than waiting for a scheduled visit.

For men with cancer in the bones, new back pain, weakness or numbness in the legs, or loss of bladder or bowel control can be signs of spinal cord compression, which is an emergency. The EAU recommends counselling men with bone metastases about these warning signs and treating compression immediately with high-dose steroids and assessment for surgery or radiation.